Risk particularly high for acute myeloid leukemia before age 5 years.
Researchers sought to determine what characteristics may drive physician decisions to give immunoglobulin supplementation for patients with B-cell ALL.
Researchers sought to determine whether combination platelet and blast counts would be a helpful predictive model for pediatric patients with ALL.
Researchers sought to determine whether NR3C1 mutations might influence glucocorticoid resistance and treatment outcomes in pediatric patients with ALL.
Researchers sought to determine whether quizartinib-based combination therapies would be safe and effective treatment options for patients with AML.
Investigators analyzed the association between hepatic SOS and short-term application of 6-TG in 3983 pediatric ALL patients.
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Reduction in fat gain not seen in overall cohort, but stratified analysis showed benefit among those overweight, obese at baseline.
Researchers sought to determine whether whole-genome sequencing may be a better risk stratification tool compared with conventional cytogenetic analysis.
Researchers sought to determine whether a lower dose of anthracycline would have the same efficacy and better safety as standard dosage in patients with APL.
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Researchers investigated whether there may be a trend of patients with AML developing symptoms of PTSD.
Researchers sought to determine whether high cortactin and HS1 expression may be linked with poorer prognosis for patients with B-ALL.
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
Researchers sought to determine whether MRD status could be a helpful prognostic tool for survival in patients with acute leukemia prior to allo-HSCT.
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Researchers sought to determine the incidence and risk factors for acute kidney in patients with AML who are undergoing induction chemotherapy.
Researchers sought to determine whether dasatinib and nilotinib would be effective second-line therapies for patients with chronic phase CML.
Researchers sought to determine whether molecular characteristics could help predict responses to treatments with venetoclax in patients with relapsed or refractory AML.
There is a need for further investigation of early intervention options for patients with early-stage CLL.
Researchers sought to see whether long-term results of a trial involving moxetumomab pasudotox would have durable response for patients with relapsed/refractory HCL.
Researchers sought to determine if immunotherapy including blinatumomab could improve disease-free survival for patients with B-cell ALL.
Researchers sought to describe a potential link between treatment with lenalidomide and development of B-cell ALL in patients with CLL.
Researchers sought to determine whether pediatric patients with ALL would have better OS if they received TBI prior to HSCT.
Cost-effectiveness model was developed to compare costs and other factors of azacitidine/venetoclax combination with azacitidine alone in patients with AML.
Researchers assessed the effectiveness of belinostat, ruxolitinib, and ibrutinib used to treat T-PLL mitochondrial priming and drug sensitivity.
Researchers revisited the techniques traditionally used to assess CNAs and translocations in routine AML diagnostics to challenge the recommended CCA.
Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
Uproleselan will be evaluated in combination with chemotherapy in a phase 3 trial of patients with relapsed or refractory acute myeloid leukemia (AML).
Increased incidence of
IKZF1 deletion and IGH-CRLF2 translocation seen in Hispanic/Latino children with B-ALL.
Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?
Researchers sought to find out if flotetuzumab shows activity with an acceptable safety profile in patients with acute myeloid leukemia and primary induction failure or early relapse.
Study authors retrospectively evaluated effect of thymoglobulin addition in RIC and MAC regimens on the cumulative incidence and severity of acute and chronic GVHD, overall survival, and relapse rate in adult AML patients who underwent URD PBSCT.
Among patients with de novo AML, fractionated-dose gemtuzumab ozogamicin does not appear to increase the risk of hepatic VOD/SOS after HSCT.
Investigators of this single-center analysis compare the incidence of CRLF2 rearrangement and IKZF1 deletion in Hispanic/Latino vs non-Hispanic/Latino children with B-cell acute lymphoblastic leukemia (B-ALL).
Researchers compare fractionated busulfan myeloablative conditioning to traditional RIC in elderly patients undergoing allogeneic hematopoietic stem cell transplantation.
A team of investigators prospectively evaluated pediatric patients with ALL to determine the effectiveness of pyridoxine (vitamin B6) plus pyridostigmine therapy for vincristine-induced neurotoxicity.
This review of the guidelines is presented as 6 questions and answers that help direct treatment decision for patients 65 and older with newly diagnosed AML.
A team of researchers identified a lack of standardized practices for treating venous thromboembolism among pediatric patients with acute lymphocytic leukemia.
A team of investigators evaluated the effect of measurable residual disease at time of allogeneic hematopoietic cell transplantation in patients with ALL undergoing transplantation during either first or second complete remission.
Among pediatric patients with relapsed or refractory acute lymphoblastic leukemia, the use of blinatumomab may provide encouraging response rates.
Investigators assessed sodium bicarbonate’s viability as a pharmacologic strategy in mouse models and humans with acute myeloid leukemia.
Investigators aimed to determine whether DPP-4 inhibition reduces the incidence of acute graft-vs-host disease among patients receiving allogeneic HSCT.
A sequenced reduced-intensity conditioning regimen may not improve outcomes for patients with acute myeloblastic leukemia and myelodysplasia after allogeneic stem cell transplantation.
This review of relevant medical literature considers concerns about the cumulative dose, dose rate, and dosing schedule of cytarabine in acute myeloid leukemia (AML).
For patients with acute myeloid leukemia, a total of 4 courses of chemotherapy may improve relapse rates but not overall survival, compared with 3 total courses of treatment.
Investigators estimated the risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) related to PARP inhibition.
This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.
Maintenance therapy with oral azacitidine leads to longer overall survival in older patients with acute myeloid leukemia.
Investigators compared outcomes of chemotherapy conditioning with total body irradiation prior to hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.